Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
International Stem Cell ( (ISCO) ) has shared an announcement.
On June 17, 2025, International Stem Cell Corporation held its Annual Meeting of Stockholders where two key proposals were considered. The first proposal involved the election of four directors, all of whom were successfully elected. The second proposal, which was approved, concerned the advisory approval of executive compensation. Additionally, a vote was held on the frequency of advisory votes on executive compensation, with the majority favoring a three-year interval.
Spark’s Take on ISCO Stock
According to Spark, TipRanks’ AI Analyst, ISCO is a Neutral.
International Stem Cell’s stock is rated low due to significant financial challenges, including negative profitability and high leverage. While there is some positive momentum in technical analysis, the valuation remains unattractive due to the lack of profitability. Improvements in financial stability and strategic changes are necessary to enhance the overall stock rating.
To see Spark’s full report on ISCO stock, click here.
More about International Stem Cell
International Stem Cell Corporation operates in the biotechnology industry, focusing on the development of stem cell-based therapies and products.
Average Trading Volume: 7,223
Technical Sentiment Signal: Buy
Current Market Cap: $1.17M
Learn more about ISCO stock on TipRanks’ Stock Analysis page.